Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.
J Biol Chem. 2013 Mar 8;288(10):6826-34. doi: 10.1074/jbc.M112.403154. Epub 2013 Jan 17.
Limit of platelet life span (8-10 days) is determined by the activity of a putative "internal clock" composed of Bcl-2 family proteins, whereas the role of other molecular players in this process remains obscure. Here, we sought to establish a central role of proteasome in platelet life span regulation. Administration of mice with inhibitors of proteasome peptidase activity induced significant thrombocytopenia. This was associated with enhanced clearance of biotin-labeled platelets from circulation and reduction in average platelet half-life from 66 to 37 h. Cells pretreated in vitro with proteasome inhibitors exhibited augmented annexin V binding and a drop in mitochondrial transmembrane potential indicative of apoptotic cell death and decreased platelet life span. These cells were preferentially phagocytosed by monocyte-derived macrophages, thus linking proteasome activity with platelet survival. The decisive role of proteasome in this process was underscored from enhanced expression of conformationally active Bax in platelets with attenuated proteasome activity, which was consistent with pro-apoptotic phenotype of these cells. The present study establishes a critical role of proteasome in delimiting platelet life span ostensibly through constitutive elimination of the conformationally active Bax. These findings bear potential implications in clinical settings where proteasome peptidase activities are therapeutically targeted.
血小板寿命(8-10 天)的限制由由 Bcl-2 家族蛋白组成的假定“内部时钟”的活性决定,而该过程中其他分子参与者的作用仍不清楚。在这里,我们试图确定蛋白酶体在血小板寿命调节中的核心作用。给予蛋白酶体肽酶活性抑制剂的小鼠会引起明显的血小板减少症。这与从循环中清除生物素标记的血小板的能力增强以及血小板平均半衰期从 66 小时减少到 37 小时有关。在体外用蛋白酶体抑制剂预处理的细胞表现出增强的膜联蛋白 V 结合和线粒体跨膜电位降低,这表明细胞凋亡和血小板寿命缩短。这些细胞被单核细胞衍生的巨噬细胞优先吞噬,从而将蛋白酶体活性与血小板存活联系起来。蛋白酶体在该过程中的决定性作用从血小板中构象活性 Bax 的表达增强得到强调,这种增强与这些细胞的促凋亡表型一致。本研究确立了蛋白酶体在限制血小板寿命方面的关键作用,显然是通过对构象活性 Bax 的持续消除来实现的。这些发现可能对临床环境具有重要意义,在这些环境中,蛋白酶体肽酶活性是治疗靶点。